Psych CASC / OSCE · General adult psychiatry — bipolar and related disorders
Explain mixed features, suicide risk, and stopping the antidepressant — CASC communication station
MRCPsych/FRANZCP-style communication station: explain mixed features and high suicide risk in plain language, justify stopping antidepressant monotherapy with STEP-BD framing, outline lithium/SGA benefits and monitoring, and check understanding.
On this page & tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes active time after reading. You are the psychiatry registrar on the inpatient unit. [3]
Candidate instructions. Explain mixed features and why this presentation is high risk for suicide. Explain why sertraline monotherapy was stopped. Outline the plan for lithium and olanzapine including common side-effects and blood tests. Briefly define rapid cycling if the partner asks about a year of many ups and downs. Check understanding and invite questions. The examiner plays the partner. [1][3]
Candidate scenario
Your patient has bipolar I disorder and was admitted after 1 week of little sleep, irritability, racing thoughts, tearfulness, and suicidal ideation. She had been on sertraline alone. She is settling on lithium plus olanzapine. Partner asks: "Why stop the antidepressant if she is depressed and suicidal? Will lithium damage her kidneys? What does mixed features mean? She has been up and down all year — is that rapid cycling?" [3]
Suggested structure (candidate)
- Rapport and agenda — acknowledge fear; set time to cover diagnosis, risk, medicines, questions.
- Mixed features in plain language — both high and low symptoms together; energy plus hopelessness is especially dangerous for suicide. [3]
- Why stop sertraline — in bipolar illness, antidepressants alone can worsen swings or mixed states; large research (STEP-BD) did not show clear long-term benefit from adding antidepressants to mood stabilisers. [1]
- Lithium and olanzapine — calm the high pole, protect mood long term; lithium has evidence linked to lower suicide risk in mood disorders; blood tests for kidney, thyroid, calcium, and lithium level; olanzapine may cause sedation and weight gain — metabolic monitoring. [2][3][4]
- Rapid cycling — four or more full episodes in a year; treatment focuses on stabilisers, sleep, and avoiding antidepressant monotherapy. [3]
- Check understanding — teach-back; safety-net who to call; written information if available.[3]
Marking domains
- Empathy, structure, and jargon control
- Accurate plain-language explanation of mixed features and suicide risk
- Clear rationale for stopping antidepressant monotherapy
- Balanced lithium/SGA benefit–risk and monitoring
- Correct rapid-cycling threshold if raised
- Collaboration and checking understanding
Actor notes (partner)
Anxious, slightly angry that the "depression tablet" was stopped. Softens if risk is explained carefully. Asks about kidney damage and whether she will be on medicines forever. May interrupt with "but she cries all the time."[3]
Common fails
- Agreeing to restart SSRI monotherapy "for the tears"[1]
- Minimising suicide risk because the patient is "activated"[3]
- Dumping technical DSM criteria without plain language
- Omitting monitoring or toxicity warning signs for lithium
- Over-reassuring that mixed features are mild
Debrief model line
"Mixed features means high-energy symptoms and low-mood symptoms happen together — that combination raises suicide risk. We stopped the antidepressant because in bipolar disorder it can make swings worse when used alone. Lithium and olanzapine treat the current mixed high pole and help prevent the next one, with blood tests to keep treatment safe." [1][2][3]
References
- [1]Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression N Engl J Med, 2007.PMID 17392295
- [2]Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ, 2013.PMID 23814104
- [3]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
- [4]Tohen M, McIntyre RS, Kanba S, et al. Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5 J Affect Disord, 2014.PMID 25046739